

Argyro Syngelaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/409962/publications.pdf>

Version: 2024-02-01

200
papers

14,257
citations

19657

61
h-index

22166

113
g-index

207
all docs

207
docs citations

207
times ranked

9114
citing authors

#	ARTICLE	IF	CITATIONS
1	Fetal fraction of cell free DNA in screening for hypertensive disorders at 11â€“13 weeks. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 5363-5368.	1.5	5
2	Screening for late preeclampsia at 35â€“37 weeks by the urinary Congo-red dot paper test. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 5686-5690.	1.5	4
3	Secondâ€trimester contingent screening for smallâ€forâ€gestationalâ€age neonate. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 59, 177-184.	1.7	12
4	<scp>STATIN</scp> trial: predictive performance of competingâ€risks model in screening for preâ€eclampsia at 35â€“37â€weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 59, 69-75.	1.7	15
5	Development and validation of model for prediction of placental dysfunctionâ€related stillbirth from maternal factors, fetal weight and uterine artery Doppler at midâ€gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 59, 61-68.	1.7	13
6	Risk of fetal loss after chorionic villus sampling in twin pregnancy derived from propensity score matching analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 59, 162-168.	1.7	9
7	Predictive performance for placental dysfunction related stillbirth of the competing risks model for smallâ€forâ€gestationalâ€age fetuses. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1530-1537.	2.3	11
8	Serum PlGF compared with PAPPâ€A in first trimester screening for preterm preâ€eclampsia: Adjusting for the effect of aspirin treatment. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1308-1317.	2.3	15
9	Sulfated Progesterone Metabolites That Enhance Insulin Secretion via TRPM3 Are Reduced in Serum From Women With Gestational Diabetes Mellitus. <i>Diabetes</i> , 2022, 71, 837-852.	0.6	3
10	Vaginal progesterone for the prevention of preterm birth and adverse perinatal outcomes in twin gestations with a short cervix: an updated individual patient data metaâ€analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 59, 263-266.	1.7	26
11	Impact of New Definitions of Preeclampsia at Term on Identification of Adverse Maternal and Perinatal Outcomes. <i>Obstetric Anesthesia Digest</i> , 2022, 42, 22-23.	0.1	0
12	Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 294.e1-294.e11.	1.3	5
13	Maternal race and preâ€eclampsia: Cohort study and systematic review with metaâ€analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 2082-2093.	2.3	8
14	Maternal Race and Stillbirth: Cohort Study and Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3452.	2.4	6
15	Detection of Embryonic Trisomy 21 in the First Trimester Using Maternal Plasma Cell-Free RNA. <i>Diagnostics</i> , 2022, 12, 1410.	2.6	3
16	Prenatal incidence of isolated right aortic arch and double aortic arch. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 2985-2990.	1.5	19
17	Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 86.e1-86.e19.	1.3	50
18	Prediction of preâ€eclampsia in twin pregnancy by maternal factors and biomarkers at 11â€“13â€weeks' gestation: data from <scp>EVENTS</scp> trial. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 57, 257-265.	1.7	21

#	ARTICLE	IF	CITATIONS
19	Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. American Journal of Obstetrics and Gynecology, 2021, 224, 518.e1-518.e11.	1.3	38
20	Competing risks model for prediction of small-for-gestational-age neonate from biophysical and biochemical markers at 11-13 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2021, 57, 52-61.	1.7	32
21	Serum leukotriene B4 and hydroxyeicosatetraenoic acid in the prediction of pre-eclampsia. Placenta, 2021, 103, 76-81.	1.5	3
22	Second and third trimester serum levels of HtrA1 in pregnancies affected by pre-eclampsia. Placenta, 2021, 106, 1-6.	1.5	2
23	Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 1635-1644.	2.3	27
24	Competing risks model for prediction of small-for-gestational-age neonates from biophysical markers at 19 to 24 weeks' gestation. American Journal of Obstetrics and Gynecology, 2021, 225, 530.e1-530.e19.	1.3	14
25	Competing risks model for prediction of small-for-gestational-age neonate from estimated fetal weight at 19-24 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2021, 57, 917-924.	1.7	14
26	Stratification of pregnancy care based on risk of pre-eclampsia derived from uterine artery Doppler at 19-24 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2021, 58, 67-76.	1.7	16
27	Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2021, 58, 360-368.	1.7	8
28	Cell-free DNA testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10-14 weeks and meta-analysis. Ultrasound in Obstetrics and Gynecology, 2021, 58, 178-189.	1.7	28
29	Effective Aspirin Treatment of Women at Risk for Preeclampsia Delays the Metabolic Clock of Gestation. Hypertension, 2021, 78, 1398-1410.	2.7	10
30	Fetal loss after chorionic villus sampling in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2021, 58, 48-55.	1.7	9
31	First-Trimester Screening for Gestational Diabetes Mellitus in Twin Pregnancies. Journal of Clinical Medicine, 2021, 10, 3814.	2.4	6
32	Competing Risks Model for Prediction of Small for Gestational Age Neonates and the Role of Second Trimester Soluble Fms-like Tyrosine Kinase-1. Journal of Clinical Medicine, 2021, 10, 3786.	2.4	2
33	Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation, 2021, 144, 670-679.	1.6	61
34	Contingent screening in stratification of pregnancy care based on risk of pre-eclampsia at 19-24 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2021, 58, 553-560.	1.7	7
35	Reference Ranges for Pulsed-Wave Doppler of the Fetal Cardiac Inflow and Outflow Tracts from 13 to 36 Weeks' Gestation. Journal of the American Society of Echocardiography, 2021, 34, 1007-1016.e10.	2.8	9
36	Estimated fetal weight at mid-gestation in prediction of pre-eclampsia in singleton pregnancies. Ultrasound in Obstetrics and Gynecology, 2021, , .	1.7	0

#	ARTICLE	IF	CITATIONS
37	Outcome of twin pregnancy with two live fetuses at 11â€“13â€“weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2020, 55, 32-38.	1.7	45
38	Intertwin discordance in fetal size at 11â€“13â€“weeks' gestation and pregnancy outcome. Ultrasound in Obstetrics and Gynecology, 2020, 55, 189-197.	1.7	32
39	Value of routine ultrasound examination at 35â€“37 weeks' gestation in diagnosis of fetal abnormalities. Ultrasound in Obstetrics and Gynecology, 2020, 55, 75-80.	1.7	59
40	Diagnosis of major heart defects by routine firstâ€“trimester ultrasound examination: association with increased nuchal translucency, tricuspid regurgitation and abnormal flow in ductus venosus. Ultrasound in Obstetrics and Gynecology, 2020, 55, 637-644.	1.7	55
41	Firstâ€“trimester screening for trisomies in pregnancies with vanishing twin. Ultrasound in Obstetrics and Gynecology, 2020, 55, 326-331.	1.7	17
42	Diagnosis of fetal defects in twin pregnancies at routine 11â€“13â€“week ultrasound examination. Ultrasound in Obstetrics and Gynecology, 2020, 55, 474-481.	1.7	24
43	Twin pregnancy with two live fetuses at 11â€“13 weeks: effect of one fetal death on pregnancy outcome. Ultrasound in Obstetrics and Gynecology, 2020, 55, 482-488.	1.7	12
44	Increased nuchal translucency at 11â€“13 weeks' gestation and outcome in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2020, 55, 318-325.	1.7	20
45	Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring. American Journal of Obstetrics and Gynecology, 2020, 223, 246.e1-246.e10.	1.3	17
46	Competingâ€“risksâ€“modelâ€“forâ€“predictionâ€“ofâ€“smallâ€“forâ€“gestationalâ€“age neonate from maternal characteristics and serum pregnancyâ€“associated plasma <scp>proteinâ€“A</scp> at 11â€“13â€“weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2020, 56, 541-548.	1.7	15
47	Galectin-7 Impairs Placentation and Causes Preeclampsia Features in Mice. Hypertension, 2020, 76, 1185-1194.	2.7	17
48	Secondâ€“and thirdâ€“trimester serum levels of growthâ€“differentiation factorâ€“15 in prediction of preâ€“eclampsia. Ultrasound in Obstetrics and Gynecology, 2020, 56, 879-884.	1.7	12
49	Screening for trisomy at 11â€“13 weeks' gestation: use of pregnancyâ€“associated plasma <scp>proteinâ€“A</scp>, placental growth factor or both. Ultrasound in Obstetrics and Gynecology, 2020, 56, 408-415.	1.7	10
50	Screening for preâ€“eclampsia at 11â€“13 weeks' gestation: use of pregnancyâ€“associated plasma <scp>proteinâ€“A</scp>, placental growth factor or both. Ultrasound in Obstetrics and Gynecology, 2020, 56, 400-407.	1.7	47
51	Metformin in Pregnancy Study (MiPS): protocol for a systematic review with individual patient data meta-analysis. BMJ Open, 2020, 10, e036981.	1.9	7
52	Diet and exercise for preeclampsia prevention in overweight and obese pregnant women: systematic review and meta-analysis. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 3495-3501.	1.5	31
53	Diagnosis of fetal nonâ€“chromosomal abnormalities on routine ultrasound examination at 11â€“13â€“weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2019, 54, 468-476.	1.7	172
54	Twoâ€“stage approach for prediction of smallâ€“forâ€“gestationalâ€“age neonate and adverse perinatal outcome by routine ultrasound examination at 35â€“37â€“weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2019, 54, 484-491.	1.7	27

#	ARTICLE	IF	CITATIONS
55	Two-stage screening for preterm preeclampsia at 11–13 weeks™ gestation. American Journal of Obstetrics and Gynecology, 2019, 220, 197.e1-197.e11.	1.3	37
56	Predictive performance of the competing risk model in screening for preeclampsia. American Journal of Obstetrics and Gynecology, 2019, 220, 199.e1-199.e13.	1.3	136
57	Fetal intra-abdominal bowel dilation in prediction of complex gastroschisis. Ultrasound in Obstetrics and Gynecology, 2019, 54, 376-380.	1.7	9
58	Routine assessment of cerebroplacental ratio at 35–37 weeks™ gestation in the prediction of adverse perinatal outcome. American Journal of Obstetrics and Gynecology, 2019, 221, 65.e1-65.e18.	1.3	50
59	Routine ultrasound at 32 vs 36 weeks' gestation: prediction of small-for-gestational-age neonates. Ultrasound in Obstetrics and Gynecology, 2019, 53, 761-768.	1.7	39
60	Prediction of imminent preeclampsia at 35–37 weeks gestation. American Journal of Obstetrics and Gynecology, 2019, 220, 584.e1-584.e11.	1.3	40
61	Prediction of small-for-gestational-age neonates at 35–37 weeks' gestation: contribution of maternal factors and growth velocity between 32 and 36 weeks. Ultrasound in Obstetrics and Gynecology, 2019, 53, 630-637.	1.7	18
62	First trimester combined screening in patients with systemic lupus erythematosus: impact of pre-analytical variables on risk assessment. Clinical Rheumatology, 2019, 38, 1251-1255.	2.2	3
63	Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35–37 weeks™ gestation. American Journal of Obstetrics and Gynecology, 2019, 220, 486.e1-486.e11.	1.3	63
64	Prediction of small-for-gestational-age neonates at 35–37 weeks' gestation: contribution of maternal factors and growth velocity between 20 and 36 weeks. Ultrasound in Obstetrics and Gynecology, 2019, 53, 488-495.	1.7	29
65	Impaired placental perfusion and major fetal cardiac defects. Ultrasound in Obstetrics and Gynecology, 2019, 53, 68-72.	1.7	13
66	Fetal Medicine Foundation reference ranges for umbilical artery and middle cerebral artery pulsatility index and cerebroplacental ratio. Ultrasound in Obstetrics and Gynecology, 2019, 53, 465-472.	1.7	122
67	First-trimester metabolomic prediction of stillbirth. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 3435-3441.	1.5	5
68	Early Detection of Preeclampsia Using Circulating Small non-coding RNA. Scientific Reports, 2018, 8, 3401.	3.3	46
69	Comparison of diagnostic accuracy of early screening for preeclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound in Obstetrics and Gynecology, 2018, 51, 743-750.	1.7	219
70	Ultrasonographic estimation of fetal weight: development of new model and assessment of performance of previous models. Ultrasound in Obstetrics and Gynecology, 2018, 52, 35-43.	1.7	109
71	Chronic Hypertension and Adverse Pregnancy Outcome: A Cohort Study. Obstetrical and Gynecological Survey, 2018, 73, 7-8.	0.4	1
72	Fetal Medicine Foundation fetal and neonatal population weight charts. Ultrasound in Obstetrics and Gynecology, 2018, 52, 44-51.	1.7	197

#	ARTICLE	IF	CITATIONS
73	Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 52-59.	1.7	91
74	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 612.e1-612.e6.	1.3	84
75	A retrospective multicenter study of the natural history of fetal ovarian cysts. <i>Journal of Pediatric Surgery</i> , 2018, 53, 2019-2022.	1.6	23
76	Two-stage approach for risk estimation of fetal trisomy 21 and other aneuploidies using computational intelligence systems. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 503-508.	1.7	18
77	Fetal major cardiac defects and placental dysfunction at 11-13 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 194-198.	1.7	24
78	Management of pregnancies after combined screening for preeclampsia at 19-24 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 365-372.	1.7	39
79	Reference Ranges for the Size of the Fetal Cardiac Outflow Tracts From 13 to 36 Weeks Gestation. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007575.	2.6	17
80	Screening for preeclampsia at 35-37 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 501-506.	1.7	58
81	Screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 186-195.	1.7	241
82	Can Staining of Damaged Proteins in Urine Effectively Predict Preeclampsia?. <i>Fetal Diagnosis and Therapy</i> , 2017, 41, 23-31.	1.4	16
83	Accuracy of competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 751-755.	1.7	182
84	Multicenter screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 756-760.	1.7	251
85	Impaired placentation in women with chronic hypertension who develop preeclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 496-500.	1.7	21
86	Chronic hypertension and adverse pregnancy outcome: a cohort study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 228-235.	1.7	112
87	Competing risks model in screening for preeclampsia in twin pregnancy by maternal characteristics and medical history. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 501-506.	1.7	25
88	Association of chronic hypertension with birth of small-for-gestational-age neonate. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 361-366.	1.7	31
89	Competing risks model in screening for preeclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 589-595.	1.7	35
90	Hidden high rate of preeclampsia in twin compared with singleton pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 88-92.	1.7	88

#	ARTICLE	IF	CITATIONS
91	Performance of the neoBona test: a new paired-end massively parallel shotgun sequencing approach for cell-free DNA-based aneuploidy screening. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 460-464.	1.7	23
92	Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin. <i>Obstetric Medicine</i> , 2017, 10, 170-173.	1.1	7
93	Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 685.e1-685.e5.	1.3	100
94	An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. <i>Scientific Reports</i> , 2017, 7, 11823.	3.3	98
95	ASPRE trial: performance of screening for preterm preeclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 492-495.	1.7	263
96	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 585.e1-585.e5.	1.3	136
97	Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. <i>New England Journal of Medicine</i> , 2017, 377, 613-622.	27.0	1,462
98	Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 714-720.	1.7	108
99	Impact of holoprosencephaly, exomphalos, megacystis and increased nuchal translucency on first-trimester screening for chromosomal abnormalities. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 45-48.	1.7	38
100	Metabolomic determination of pathogenesis of late-onset preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017, 30, 658-664.	1.5	35
101	Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 194-200.	1.7	21
102	Integrated Proteomic and Metabolomic prediction of Term Preeclampsia. <i>Scientific Reports</i> , 2017, 7, 16189.	3.3	33
103	Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 47, 332-339.	1.7	40
104	Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. <i>Hepatology</i> , 2016, 63, 1287-1298.	7.3	85
105	Prediction of stillbirth from maternal factors, fetal biometry and uterine artery Doppler at 19-24 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 48, 624-630.	1.7	21
106	Birth weight in live births and stillbirths. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 48, 602-606.	1.7	106
107	Prediction of stillbirth from maternal demographic and pregnancy characteristics. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 48, 607-612.	1.7	39
108	A Randomized Trial of a Cervical Pessary to Prevent Preterm Singleton Birth. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 392-393.	0.4	2

#	ARTICLE	IF	CITATIONS
109	Metformin Versus Placebo in Obese Pregnant Women Without Diabetes Mellitus. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 324-326.	0.4	2
110	A Randomized Trial of a Cervical Pessary to Prevent Preterm Singleton Birth. <i>New England Journal of Medicine</i> , 2016, 374, 1044-1052.	27.0	156
111	Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2016, 374, 434-443.	27.0	308
112	First trimester screening for gestational diabetes mellitus by maternal factors and markers of inflammation. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 131-137.	3.4	41
113	Cervical pessary placement for prevention of preterm birth in unselected twin pregnancies: a randomized controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 3.e1-3.e9.	1.3	120
114	Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 103.e1-103.e12.	1.3	365
115	Association between maternal haemoglobin at 27-29 weeks gestation and intrauterine growth restriction. <i>Pregnancy Hypertension</i> , 2015, 5, 339-345.	1.4	12
116	First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History. <i>Fetal Diagnosis and Therapy</i> , 2015, 38, 14-21.	1.4	58
117	Competing risks model in screening for preeclampsia by maternal characteristics and medical history. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 62.e1-62.e10.	1.3	280
118	First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1485-1489.	3.4	45
119	Maternal hemoglobin at 27-29 weeks gestation and severity of pre-eclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 28, 1575-1580.	1.5	5
120	The role and interaction of imprinted genes in human fetal growth. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140074.	4.0	113
121	Metabolomic Prediction of Fetal Congenital Heart Defect in the First Trimester. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 9-11.	0.4	2
122	Is variation in copy number of the human beta defensin gene cluster associated with preterm birth?. <i>Lancet, The</i> , 2015, 385, S47.	13.7	0
123	Umbilical and fetal middle cerebral artery Doppler at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 82-92.	1.7	85
124	Validation of metabolomic models for prediction of early-onset preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 530.e1-530.e10.	1.3	51
125	A Case-Control Study of Maternal Periconceptual and Pregnancy Recreational Drug Use and Fetal Malformation Using Hair Analysis. <i>PLoS ONE</i> , 2014, 9, e111038.	2.5	20
126	8.4-...Serum beta defensin concentration in the first trimester is related to genotype, and is higher in women who develop PPRM and deliver before 34 weeks. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2014, 99, A12.1-A12.	2.8	2

#	ARTICLE	IF	CITATIONS
127	First-Trimester Screening for Trisomies 21, 18 and 13 by Ultrasound and Biochemical Testing. Fetal Diagnosis and Therapy, 2014, 35, 118-126.	1.4	108
128	Assessment of Fetal Sex Chromosome Aneuploidy Using Directed Cell-Free DNA Analysis. Obstetrical and Gynecological Survey, 2014, 69, 249-250.	0.4	3
129	Fetal Fraction Estimate in Twin Pregnancies Using Directed Cell-Free DNA Analysis. Fetal Diagnosis and Therapy, 2014, 35, 199-203.	1.4	55
130	Assessment of Fetal Sex Chromosome Aneuploidy Using Directed Cell-Free DNA Analysis. Fetal Diagnosis and Therapy, 2014, 35, 1-6.	1.4	81
131	Prenatal Detection of Fetal Triploidy from Cell-Free DNA Testing in Maternal Blood. Fetal Diagnosis and Therapy, 2014, 35, 212-217.	1.4	96
132	Metabolomic prediction of fetal congenital heart defect in the first trimester. American Journal of Obstetrics and Gynecology, 2014, 211, 240.e1-240.e14.	1.3	48
133	Replacing the Combined Test by Cell-Free DNA Testing in Screening for Trisomies 21, 18 and 13: Impact on the Diagnosis of Other Chromosomal Abnormalities. Fetal Diagnosis and Therapy, 2014, 35, 174-184.	1.4	51
134	A Comprehensive Analysis of Common Genetic Variation Around Six Candidate Loci for Intrahepatic Cholestasis of Pregnancy. American Journal of Gastroenterology, 2014, 109, 76-84.	0.4	103
135	Cell-Free DNA Analysis for Trisomy Risk Assessment in First-Trimester Twin Pregnancies. Fetal Diagnosis and Therapy, 2014, 35, 204-211.	1.4	92
136	Association of DEFB1 polymorphisms and in-vivo protein expression: a population-based, case-control study. Lancet, The, 2014, 383, S59.	13.7	1
137	First-Trimester Contingent Screening for Trisomies 21, 18 and 13 by Biomarkers and Maternal Blood Cell-Free DNA Testing. Fetal Diagnosis and Therapy, 2014, 35, 185-192.	1.4	51
138	Paternally Expressed, Imprinted Insulin-Like Growth Factor-2 in Chorionic Villi Correlates Significantly with Birth Weight. PLoS ONE, 2014, 9, e85454.	2.5	38
139	Maternal Age and Adverse pregnancy outcome: A cohort study. Ultrasound in Obstetrics and Gynecology, 2013, 42, 634-643.	1.7	275
140	Maternal Serum Soluble Endoglin at 30-33 Weeks in the Prediction of Preeclampsia. Fetal Diagnosis and Therapy, 2013, 33, 149-155.	1.4	15
141	Trisomy 13 detection in the first trimester of pregnancy using a chromosome selective cell-free DNA analysis method. Ultrasound in Obstetrics and Gynecology, 2013, 41, 21-25.	1.7	100
142	Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound in Obstetrics and Gynecology, 2013, 41, 26-32.	1.7	325
143	First-trimester uterine artery Doppler examination in pregnancies complicated by gestational diabetes mellitus with or without pre-eclampsia. Ultrasound in Obstetrics and Gynecology, 2013, 42, 525-529.	1.7	14
144	Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers. Fetal Diagnosis and Therapy, 2013, 33, 8-15.	1.4	464

#	ARTICLE	IF	CITATIONS
145	Validation of targeted sequencing of single nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. <i>Prenatal Diagnosis</i> , 2013, 33, 575-579.	2.3	202
146	Combined Screening for Preeclampsia and Small for Gestational Age at 11–13 Weeks. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 16-27.	1.4	180
147	Second-Trimester Uterine Artery Doppler in the Prediction of Stillbirths. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 28-35.	1.4	43
148	A robust second-generation genome-wide test for fetal aneuploidy based on shotgun sequencing cell-free DNA in maternal blood. <i>Prenatal Diagnosis</i> , 2013, 33, 707-710.	2.3	49
149	Maternal serum placental growth factor at 11–13 weeks' gestation and fetal cardiac defects. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 169-174.	1.7	39
150	Maternal Age and Adverse Pregnancy Outcomes. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 779-781.	0.4	1
151	Prediction of Preeclampsia by Uterine Artery Doppler at 20-24 Weeks' Gestation. <i>Fetal Diagnosis and Therapy</i> , 2013, 34, 241-247.	1.4	31
152	First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 41-50.	1.7	107
153	Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 215-223.	1.4	179
154	Maternal serum activin-A at 30–33 weeks in the prediction of preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 733-737.	1.5	10
155	4.2...Variation in Beta Defensin 1 Genotype is Associated with Preterm Birth. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2013, 98, A4.1-A4.	2.8	0
156	Noninvasive Prenatal Testing for Fetal Trisomies in a Routinely Screened First-Trimester Population. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 173-175.	0.4	13
157	Maternal racial origin and adverse pregnancy outcome: a cohort study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 41, 278-285.	1.7	83
158	Protocol for Measurement of Mean Arterial Pressure at 11-13 Weeks' Gestation. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 42-48.	1.4	197
159	A Competing Risks Model in Early Screening for Preeclampsia. <i>Fetal Diagnosis and Therapy</i> , 2012, 32, 171-178.	1.4	182
160	A Mixture Model of Ductus Venosus Pulsatility Index in Screening for Aneuploidies at 11–13 Weeks' Gestation. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 221-229.	1.4	31
161	Birthweight with Gestation and Maternal Characteristics in Live Births and Stillbirths. <i>Fetal Diagnosis and Therapy</i> , 2012, 32, 156-165.	1.4	111
162	Maternal Hemodynamics at 11–13 Weeks of Gestation in Pregnancies Delivering Small for Gestational Age Neonates. <i>Fetal Diagnosis and Therapy</i> , 2012, 32, 231-238.	1.4	25

#	ARTICLE	IF	CITATIONS
163	Maternal Serum Placental Growth Factor in Prospective Screening for Aneuploidies at 8â€“13 Weeksâ€™ Gestation. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 87-93.	1.4	54
164	First-Trimester Screening for Spontaneous Preterm Delivery with Maternal Characteristics and Cervical Length. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 154-161.	1.4	93
165	Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, 374.e1-374.e6.	1.3	323
166	Fetal Fraction in Maternal Plasma Cell-Free DNA at 11â€“13 Weeksâ€™ Gestation: Effect of Maternal and Fetal Factors. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 237-243.	1.4	132
167	OS027. Ethnicity and adverse pregnancy outcomes: A cohort study. <i>Pregnancy Hypertension</i> , 2012, 2, 190-191.	1.4	0
168	OS084. Maternal haemodynamics at 11â€“13 weeks of gestation and adverse pregnancy outcomes. <i>Pregnancy Hypertension</i> , 2012, 2, 223-224.	1.4	2
169	Maternal Hemodynamics in Normal Pregnancies at 11â€“13 Weeksâ€™ Gestation. <i>Fetal Diagnosis and Therapy</i> , 2012, 32, 179-185.	1.4	19
170	Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, Downâ€™s syndrome, preterm delivery and preeclampsia. <i>Reproductive Biology and Endocrinology</i> , 2012, 10, 113.	3.3	17
171	Maternal hemodynamics at 11â€“13 weeks' gestation and risk of preâ€™clampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2012, 40, 28-34.	1.7	76
172	Posterior brain in fetuses with trisomy 18, trisomy 13 and triploidy at 11 to 13 weeks' gestation. <i>Prenatal Diagnosis</i> , 2012, 32, 854-858.	2.3	24
173	Yolk Sac Diameter in Early Pregnancy in Maternal Diabetes Mellitus. <i>Gynecologic and Obstetric Investigation</i> , 2012, 73, 16-20.	1.6	3
174	First trimester maternal serum free Î²â€™human chorionic gonadotropin and pregnancyâ€™associated plasma protein A in pregnancies complicated by diabetes mellitus. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 410-416.	2.3	50
175	Chromosome-selective sequencing of maternal plasma cellâ€™free DNA for first-trimester detection of trisomy 21 and trisomy 18. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 322.e1-322.e5.	1.3	245
176	First-Trimester Prediction of Macrosomia. <i>Fetal Diagnosis and Therapy</i> , 2011, 29, 139-147.	1.4	57
177	Prevalence and Outcome of Absence of Ductus Venosus at 11<sup>+0</sup> to 13<sup>+6</sup> Weeks. <i>Fetal Diagnosis and Therapy</i> , 2011, 30, 35-40.	1.4	47
178	Contribution of Fetal Tricuspid Regurgitation in First-Trimester Screening for Major Cardiac Defects. <i>Obstetrics and Gynecology</i> , 2011, 117, 1384-1391.	2.4	97
179	First-trimester markers of aneuploidy in women positive for HIV. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2011, 118, 844-848.	2.3	12
180	Sonographic markers of aneuploidies at 6â€“10weeks of gestation. <i>Early Human Development</i> , 2011, 87, 453-456.	1.8	62

#	ARTICLE	IF	CITATIONS
181	Prediction of outcome in dichorionic twin pregnancies at 6-10 weeks' gestation. American Journal of Obstetrics and Gynecology, 2011, 205, 348.e1-348.e5.	1.3	13
182	First-Trimester Screening for Trisomy 21 Using Alpha-Fetoprotein. Fetal Diagnosis and Therapy, 2011, 30, 215-218.	1.4	19
183	Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenatal Diagnosis, 2011, 31, 135-141.	2.3	187
184	Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenatal Diagnosis, 2011, 31, 90-102.	2.3	385
185	Screening for trisomies in dichorionic twins by measurement of fetal nuchal translucency thickness according to the mixture model. Prenatal Diagnosis, 2011, 31, 16-21.	2.3	24
186	Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenatal Diagnosis, 2011, 31, 66-74.	2.3	377
187	Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks. Prenatal Diagnosis, 2011, 31, 75-83.	2.3	101
188	Contribution of Method of Conception on Pregnancy Outcome after the 11-13 Weeks Scan. Fetal Diagnosis and Therapy, 2011, 30, 9-22.	1.4	32
189	Contribution of Ductus Venosus Doppler in First-Trimester Screening for Major Cardiac Defects. Fetal Diagnosis and Therapy, 2011, 29, 127-134.	1.4	80
190	Body Mass Index at 11-13 Weeks' Gestation and Pregnancy Complications. Fetal Diagnosis and Therapy, 2011, 30, 250-265.	1.4	52
191	First-Trimester Screening for Trisomy 21 with Adjustment for Biochemical Results of Previous Pregnancies. Fetal Diagnosis and Therapy, 2011, 30, 194-202.	1.4	8
192	Ultrasonographic prediction of early miscarriage. Human Reproduction, 2011, 26, 1685-1692.	0.9	69
193	Chorionic Villus Sampling at 11 to 13 Weeks of Gestation and Hypertensive Disorders in Pregnancy. Obstetrical and Gynecological Survey, 2010, 65, 751-752.	0.4	0
194	The 11-13-week scan: diagnosis and outcome of holoprosencephaly, exomphalos and megacystis. Ultrasound in Obstetrics and Gynecology, 2010, 36, 10-14.	1.7	91
195	Maternal serum human placental growth hormone at 11 to 13 weeks in trisomy 21 and trisomy 18 pregnancies. Prenatal Diagnosis, 2010, 30, 212-215.	2.3	4
196	Effect of Chorionic Villus Sampling on Uterine Artery Doppler. Fetal Diagnosis and Therapy, 2010, 28, 9-13.	1.4	5
197	Normal Ranges of Embryonic Length, Embryonic Heart Rate, Gestational Sac Diameter and Yolk Sac Diameter at 6-10 Weeks. Fetal Diagnosis and Therapy, 2010, 28, 207-219.	1.4	76
198	Chorionic Villus Sampling at 11 to 13 Weeks of Gestation and Hypertensive Disorders in Pregnancy. Obstetrics and Gynecology, 2010, 116, 374-380.	2.4	12

#	ARTICLE	IF	CITATIONS
199	Recreational drug use is associated with a variety of fetal malformations. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2010, 95, Fa21-Fa21.	2.8	0
200	Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenatal Diagnosis, 2009, 29, 1103-1108.	2.3	97